Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis/cystitis and review of the literature

Frontiers in Immunology

Immunology

Qihao Zhou¹  Qunjiang Wang¹  Peiyuan Yan¹  Jing Qu¹  Zhiquan Qin¹  Yun Chen¹ 

[1] Cancer Center, Department of Medical Oncology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, China;

关键词: immune-related adverse events;    tislelizumab;    cystitis;    ureteritis;    case report;   

DOI  :  10.3389/fimmu.2023.1226993

 received in 2023-05-22, accepted in 2023-09-25,  发布年份 2023

来源: Frontiers

【 摘 要 】

Immune checkpoint inhibitor (ICI) is an up-to-date therapy for cancer with a promising efficacy, but it may cause unique immune-related adverse events (irAEs). Although irAEs could affect any organ, irAEs-induced whole urinary tract expansion was rarely reported. Herein, we reported a 27-year-old male patient with thymic carcinoma who received the treatment of tislelizumab, paclitaxel albumin and carboplatin. He was hospitalized for severe bellyache and lumbago after 6 courses of treatment. Antibiotic and antispasmodic treatment did not relieve his symptoms. The imaging examinations reported whole urinary tract expansion and cystitis. Therefore, we proposed that the patient’s pain was caused by tislelizumab-induced ureteritis/cystitis. After the discontinuation of tislelizumab and the administration of methylprednisolone, his symptoms were markedly alleviated. Herein, we reported a rare case of ICI-induced ureteritis/cystitis in the treatment of thymic cancer and reviewed other cases of immunotherapy-related cystitis and tislelizumab-related adverse events, which will provide a reference for the diagnosis and treatment of ICI-related irAEs.

【 授权许可】

Unknown   
Copyright © 2023 Zhou, Qin, Yan, Wang, Qu and Chen